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ScienceDirectThe healthy immune system protects against infection and
malignant transformation without causing significant damage
to host tissues. Immune dysregulation results in diverse
pathologies including autoimmune disease, chronic
inflammatory disorders, allergies as well as immune
deficiencies and cancer. Phosphoinositide 3-kinase (PI3K)
signalling has been shown to be a key pathway in the
regulation of the immune response and continues to be the
focus of intense research. In recent years we have gained
detailed understanding of PI3K signalling, and saw the
development of potent and highly selective small molecule
inhibitors, of which several are currently in clinical trials for the
treatment of immune-related disorders and cancer. The role
of PI3K signalling in the immune response has been the
subject of detailed reviews; here we focus on relevant recent
progress in pre-clinical and clinical development of PI3K
inhibitors.
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PI3K signalling
The PI3Ks are a family of lipid kinases that phosphory-
late the 3rd hydroxyl on phosphoinositides in cell mem-
branes. Structurally, these enzymes share a common
PI3K core motif, consisting of a C2 domain, a helical
domain and a catalytic (kinase) domain. PI3Ks are clas-
sified into three families based on structure and substrate
specificity, with the class I PI3K being further subdi-
vided into class IA and class IB, summarised in Table 1
and Figure 1 [1–3].Current Opinion in Pharmacology 2015, 23:82–91 Class I PI3K
Gene targeted mouse models exist for all the class I PI3K
catalytic and regulatory subunits and, together with the
availability of isoform specific inhibitors, have greatly
enhanced our understanding of PI3K signalling. Class I
PI3K function as heterodimers consisting of a regulatory
subunit associated with a catalytic subunit and phosphor-
ylate PI(4,5)P2 to form PI(3,4,5)P3 which recruits pleck-
strin homology(PH)-domain containing effector proteins
such as AKT (PKB) to the cell membrane [2]. Under most
circumstances class IA enzymes are activated through
receptor tyrosine kinases (RTK) and other tyrosine kinase
coupled receptors, while the class IB isoform p110g is
activated through G-protein coupled receptors (GPCRs).
However, this distinction is becoming increasingly un-
clear: p110b can be activated by GPCRs [1,2], and one
study found that p110g function downstream of RTK,
TLR and type-I cytokine receptors [4].
Class I PI3Ks play an important role in immune regula-
tion, and the four isoforms differ in terms of tissue
distribution and function: PI3Ka is ubiquitously
expressed and essential for angiogenesis and insulin
signalling [5]. PI3Ka can also compensate for the loss
of PI3Kd during early B cell development [6]. Like
PI3Ka, PI3Kb is ubiquitously expressed, but plays a
non-redundant role in Fcg receptor-dependent phago-
cytosis and ROS production in macrophages and neu-
trophils [7,8]. PI3Kd and PI3Kg expression is mainly
restricted to leukocytes, and their expression levels
and function vary based on cell type and activation
conditions. PI3Kd function is critical for mature B cell
development as well as effector T cell and regulatory T
cell (Treg) differentiation and function [6,9–11]. PI3Kd
and PI3Kg can act synergistically to modulate myeloid
effector function: sequential PI3Kg and PI3Kd activation
is required for effective ROS production in human, but
not mouse neutrophils [12], and aberrant migration in
aged neutrophils could be partially corrected by PI3Kd
(CAL-101) or PI3Kg (AS252424) inhibitors [13]. The
relative contribution of PI3Kd and PI3Kg to mast cell
function is still controversial: while some studies found
PI3Kg signalling to be critical for mast cell infiltration
and degranulation, with transient inhibition of p110g
with NVS-PI-4 sufficient to prevent mast cell extravasa-
tion in a passive cutaneous anaphylaxis (PCA) model
[14,15], another study showed an essential role for PI3Kd,
but not PI3Kg, signalling in PCA induced mast cell
extravasation [16]. PI3Kb, PI3Kd and PI3Kg alsowww.sciencedirect.com
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Table 1
Summary of PI3K classes
Isoforms Tissue distribution Substrate Product Adaptor molecules
Class IA p110a Ubiquitous PI(4,5)P2 PI(3,4,5)P3
aka PIP3
p85a(p50a,p55a)
p85b; p55g
p110b Ubiquitous
p110d Leukocytes, neurons
Class IB p110g Leukocytes, cardiac myocytes PI(4,5)P2 PI(3,4,5)P3 p101/p84/p87
Class II C2a Epithelium, endothelium PI, PI4P PI3P, PI(3,4)P2
C2b Ubiquitous
C2g Hepatocytes
Class III VPS34 Ubiquitous PI PI3P VPS15(p150)contribute to optimal dendritic cell (DC) and macro-
phage function [1,17].
PI3K signalling can promote pro-inflammatory cytokine
production through NFkB activation downstream of AKT
and mediate IL-6 secretion in response to CD80/CD86
stimulation in DC [18]. However, PI3K also play a
regulatory role in certain innate immune responses. Sev-
eral studies identified an inhibitory role for PI3K signal-
ling in TLR mediated inflammation: PI3Kd activation
downstream of TIRAP-MyD88 dependent (TLR2,
TLR4) and TRAM-TRIF dependent (TLR4, TLR3)
stimulation inhibits pro-inflammatory cytokine secretion
while increasing the production of IL-10 in macrophages
and DC [19–24]. Possible mechanisms are thought to be
through AKT-dependent inhibition of GSK3b, leading to
increased levels of CREB and competitive inhibition ofFigure 1
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Schematic representation of class I-III PI3K structures ABD: adaptor binding
domain; KD: kinase domain; PR: proline rich domain; PX: phox homology d
domain); iSH2: inter-SH2 domain (p110 binding domain). Complexes betwe
subunits are often referred to as PI3Ka, PI3Kb, PI3Kd and PI3Kg.
www.sciencedirect.com NFkB-p65 and AKT dependent inhibition of FoxO1
[23,24]. TLR4 is unique in being activated via a TIRAP
dependent mechanism on the cell membrane and also via
TRAM following endocytosis. PI3Kd can mediate a
switch between TIRAP dependent pro-inflammatory cy-
tokine secretion and TRAM-dependent IL-10 secretion,
thereby limiting inflammation and protecting mice from
LPS induced endotoxic shock [21]. PI3Kd can also control
type I IFN production by regulating IRF-7 nuclear trans-
location in human plasmacytoid DC [25]. PI3Kd could
therefore be a promising therapeutic target in diseases
where this pro-inflammatory response is dysregulated.
Physiologically, PI3K is regulated by phosphatase and
tensin homolog (PTEN) which reverts PIP3 to
PI(4,5)P2. Myeloid cell-specific PTEN deficiency leads
to increased PIP3 levels, reduced inflammation, increased
macrophage phagocytic ability and resistance to infectionSH2
RBD C2 HD KD
p85α regulatory subunit
p110 catalytic subunit
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 domain; RBD: RAS binding domain; C2: C2 domain; HD: helical
omain; BH: breakpoint cluster region homology domain (Rho-Gap-like
en p110a, p110b, p110d and p110g and their respective regulatory
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84 Immunomodulationin mice [26]. Similarly, aged macrophages show increased
expression of PI3Kd with decreased pro-inflammatory
cytokine production in response to TLR stimulation,
which is partially reversed by the pan-class I PI3K inhibi-
tor LY924002 [20]. Recently it was also shown that
LY924002 can reduce TLR3 dependent IL-10 secretion
in BCG infected macrophages [22].
Together, these studies show that the PI3K/AKT signal-
ling pathway plays a complex role in orchestrating both
pro-inflammatory and anti-inflammatory pathways to
maintain effective immunity while protecting host tissues
(Figure 2).
Targeting class I PI3K in autoimmune and
inflammatory disorders
Autoimmune disease results from a breakdown in toler-
ance leading to an immune response directed against host
cells, causing conditions such as multiple sclerosis (MS),
systemic lupus erythematosus (SLE), rheumatoid arthri-
tis (RA), psoriasis and autoimmune (type I) diabetes.Figure 2
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Current Opinion in Pharmacology 2015, 23:82–91 Chronic inflammatory conditions such as chronic obstruc-
tive pulmonary disease (COPD), atherosclerosis and in-
flammatory bowel disease (IBD) arise from failure to
resolve an ongoing immune response [1,27]. Several of
the driving factors of COPD and atherosclerosis have
been identified. In atherosclerosis patients oxidised
LDL promotes arterial inflammation, while in a large
number of COPD patients cigarette smoke contributes to
the pathogenesis. However, it is clear that pathogen-
driven responses trigger exacerbations in COPD patients
which lead to worsened inflammation and a general
decline in health status [28]. Allergic conditions such
as asthma or anaphylaxis are caused by an inappropriate
immune response directed against a normally harmless
antigen [1]. Uncontrolled inflammation is also a risk factor
for the development of cancer, and has been shown to
contribute to tumour growth and metastasis [5].
PI3Kd and PI3Kg are extensively studied as potential
targets for anti-inflammatory treatments and the fact that
these isoforms have complementary roles in many aspectsIntegrinReceptor
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therapeutic use of PI3Kd and/or PI3Kg inhibitors (see
Table 2 for inhibitors in clinical trials and Table 3 for
inhibitors used in pre-clinical models). Indeed, inhibiting
PI3Kd and PI3Kg in different mouse models of inflam-
matory disease produced promising results: the dual
PI3Kd/g inhibitor TG100-115 reduced inflammatory cell
infiltrates in an OVA-induced asthma model as well as in
smoke-induced and LPS-induced models of airway in-
flammation when administered as an aerosol [29]. More
recently another dual selective PI3Kd/g inhibitor, IP-145
(duvelisib), administered systemically also reduced eo-
sinophil infiltration in an OVA-induced asthma model
[30]. Interestingly, these preclinical models show that
both inhaled and systemic administration routes are ef-
fective. Selective PI3Kd inhibition was found to restore
glucocorticoid sensitivity in smoke-induced COPD mod-
els by preventing tyrosine nitration of HDAC-2 [31]
and IC87114, a selective PI3Kd inhibitor, reducedTable 2
Class I PI3K/mTOR inhibitors in clinical trials
Compound Target 
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www.sciencedirect.com inflammatory cell infiltrates and IL-17 secretion in an
OVA-induced asthma model [32]. PI3Kd kinase dead
mice are also protected against OVA-induced airway
eosinophilia due to decreased Th2, but not Th1 mediated
inflammation [33]. Collectively, these data show that class
I PI3K signalling may play a key role in the pathogenesis
of COPD and asthma [28,34]. This is strengthened by the
observation that aberrant migration and decreased accu-
racy of human neutrophils derived from COPD patients is
corrected by PI3Kd inhibition [35]. However, increased
neutrophil survival is also an important aspect of COPD
and this was not influenced by isoform-selective PI3K
inhibition [36]. GSK recently developed an inhaled p110d
inhibitor GSK2269557 which is currently in phase 2 clini-
cal trials for COPD and asthma (NCT02294734). Another
approach to PI3Kd inhibition is being developed by
Aquinox: their SHIP-1 activator AQX-1125 is being test-
ed in a phase 2 study in exacerbating COPD patients
(NCT01954628).Indication Clinical trial identifier
rrent or Metastatic
mous Cell Carcinoma
NCT02145312, Phase 1/2
nced Nonhaematologic
nancies
NCT01899053, Phase 1b
latelet Effect NCT00853450, Phase 1
atologic Malignancies NCT01300026, Phase 1
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Hodgkin Lymphoma
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Table 3
Some isoform-selective PI3K inhibitors used in pre-clinical studies: IC50 mM
Compound Target p110a p110b p110d p110g Vps34 Ref.
A66 p110a 0.032 0.236 1.25 3.48 [1]
NVS-PI3-2 p110a 0.075 5.5 0.98 2.4 [36]
PW12 p110a 0.015 0.83 0.73 0.97 [17]
HBC-417 p110b 0.38 0.007 0.03 0.2 [36]
TGX-115 p110b 61 0.13 0.63 >100 [17]
TGX-221 p110b 5 0.007 0.1 3.5 [1]
AS252424 p110g 1.07 >20 >20 0.035 [12]
AS614006 p110g 1.68 0.062 0.166 0.003 [43]
AS605240 p110g 0.06 0.27 0.3 0.008 [1] [52]
CZC24832 p110g >10 1.1 8.2 0.027 [80]
NVS-PI3-4 p110g 1.8 0.25 0.75 0.09 [36]
TASP0415914a p110g 0.029 [51]
GS-9820 p110d 5.441 3.377 0.012 1.389 12.685 [79]
GS-9829 p110d >10 >10 0.0703 >10 >10 [48]
IC87114 p110d >100 5 0.1 1 [1]
NVS-PI3-3 p110d 0.18 0.6 0.003 0.31 [36]
PI-3065 p110d 0.91 0.6 0.005 >1000 [41]
YM-024 p110a/p110d 0.3 2.65 0.33 9.07 [36]
TG100-115 p110d/p110g 1300 1200 0.235 0.083 [81]
PI-103 pan-class I 0.0008 0.088 0.048 0.15 [36]
wortmannin pan-PI3K/mTOR 0.001 0.01 0.005 0.009 [36]
LY294002 pan-PI3K/mTOR 0.7 0.306 1.33 7.26 [36]
PIK-III VPS34 3.96 >9.1 1.2 3.04 0.018 [75]
SAR405 VPS34 >10 >10 >10 >10 0.0012 [74]
VPS34-IN1 VPS34 8.036 21.44 1.896 2 0.025 [76]
a No selectivity data published.Experimental autoimmune encephalitis (EAE) is a model
for multiple sclerosis. EAE progression is mainly driven by
Th17 mediated inflammation of the CNS leading to the
destruction of myelin, with antigen presenting cells (APC)
playing a key role in the amplification of inflammation [37].
Genetic and pharmacological inhibition of PI3Kg signifi-
cantly reduced CNS inflammation and disease progression
[38,39], while PI3Kd kinase dead mice also showed re-
duced disease severity in conjunction with a defective
Th17 response [40]. However, PI3Kd signalling is also
essential for the optimal development and function of
Treg [10,11,41]. In fact, our data indicate that despite
reduced Th17 and Th1 responses, p110d kinase dead mice
are not protected against EAE progression, likely due to a
concomitant reduction in Treg (A Stark, E Slack, K Okken-
haug, unpublished). Furthermore, PTEN deficient macro-
phages show increased expression/secretion of arginase I,
which could inhibit the pro-inflammatory effects of DC
and T cells and protect mice against EAE [42]. Psoriasis is
also a Th17 driven disease and may benefit from PI3Kd
and/or PI3Kg inhibition. Imiquimod-induced skin inflam-
mation was reduced in PI3Kg deficient and PI3Kd kinase
dead mice, while PI3Kd (IC87114) and PI3Kg (AS605240
and AS614006) inhibitors reduced pro-inflammatory cyto-
kine secretion in human CD4+memory T cells and PBMC
from psoriasis patients [43]. Inhibiting PI3Kd using
IC87114 improved graft survival in a mouse heart trans-
plant model [44] and delayed disease progression the NOD
mouse model of diabetes [45].Current Opinion in Pharmacology 2015, 23:82–91 PI3Kd and PI3Kg inhibition also attenuate disease
progression in mouse models of SLE [46–50]. SLE is
driven by autoreactive T cells and B cells, with renal
immune complex deposition and macrophage driven
inflammation key features of the disease. Treatment
of MRL/lpr mice with the PI3Kd selective inhibitor GS-
9829 reduced kidney damage and prolonged life span.
GS-9829 decreased effector-memory T cells and serum
IL-6 and TNF-a levels, and also reduced macrophage
infiltration in the kidneys [48]. These results were
corroborated by another study reporting that the PI3Kd
selective inhibitor MSC2360844 can inhibit pro-inflam-
matory cytokine secretion by B cells, T cells and DC,
and improve renal disease in a NZBW F1 mouse model
[49]. Interestingly, haploinsufficient p110dWT/D910A
showed resistance to an autoreactive B cell driven
lupus-like syndrome when crossed to a Lyn/ back-
ground, by a mechanism that appear to involve attenu-
ated T cell function [50]. Treatment with the PI3Kd
inhibitor IC87114 also improved disease outcome in the
BXSB model of SLE [46] and the PI3Kg inhibitor
AS605240 was effective in reducing disease severity
and increasing life-span in MRL/lpr mice [47]. Further-
more the dual p110d/p110g inhibitor IP-145 inhibited
disease progression the NZBWF1/J mouse model of
SLE [30].
Inhibitors of PI3Kd, PI3Kg and dual selective inhibition
are also effective in alleviating the symptoms of RA inwww.sciencedirect.com
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TASP0415914 and CZC24823 reduced the development
of collagen induced arthritis (CIA) [39,51,52], and genet-
ic as well as pharmacological inhibition improved symp-
toms in the effector phase K/BxN serum transfer and
aCII models, mainly driven by neutrophilic inflamma-
tion [52,53]. Neutrophil migration to LTB4 is markedly
reduced by dual PI3Kg/d inhibition compared to inhibi-
tion of either isoform alone [53]. However, while the dual
PI3Kg/d inhibitor IP-145 could significantly reduce an-
kle swelling in a rat CIA model [30], it did not improve
RA scores in a recent phase 2 clinical trial, showing that
animal models do not always predict clinical outcomes in
patients. Using the K/BxN mouse model, a separate
study show reduced disease development in PI3Kb
deficient mice at low, but not high doses of serum
transfer, while additional PI3Kd deficiency markedly
reduced disease severity at high serum transfer doses,
indicating a role for dual PI3Kd/PI3Kb inhibitors in this
context [7].
ZSTK474 is a pan-class I PI3K inhibitor, and was also
found to reduce inflammation and disease progression in
RA and EAE mouse models [54,55]. However, there is a
greater risk of adverse side effects when inhibiting PI3Ka
and PI3Kb in addition to PI3Kd and/or PI3Kg. Results
from clinical trials show that pan-class I inhibitors are
associated with hyperglycaemia, gastrointestinal and psy-
chiatric effects [56]. Moreover, pan-class I inhibitors do
not necessarily control inflammation better than dual
PI3Kd/PI3Kg inhibitors [57].
PI3Kd and PI3Kg single and dual isoform selective
inhibitors are generally well tolerated in mouse models,
and mice deficient in p110d or p110g do not show overt
clinical phenotypes despite established immunological
defects. There is considerable redundancy among the
PI3K isoforms and not all immune functions are PI3K
dependent. Therefore, selective inhibition is likely to
blunt, rather than completely ablate immune function.
Mice are normally kept under specific pathogen free
(SPF) conditions and are not exposed to common
pathogens and co-morbidities; therefore potential in-
creased susceptibility to infection needs to be consid-
ered in human trials [58]. Serious side effects were
reported for patients treated with the PI3Kd selective
inhibitor idelalisib which included neutropenia, pneu-
monitis, colitis, diarrhoea and evidence of liver damage
as indicated by the black box label attached to Zydelig
(Idelalisib) [59,60]. Among these, colitis appears to be
the most common and it is worth noting that the kinase
dead p110dD910A mice predicted PI3K inhibition can
cause colitis [61]. The side effects associated with
idelalisib suggest that transient, low dose, or local
administration such as inhalation of PI3Kd inhibitors
should be considered to manage inflammatory condi-
tions where possible.www.sciencedirect.com Increased class I PI3K signalling is a cause of
primary immunodeficiency
Recently, autosomal dominant gain of function mutations
of PIK3CD (encoding p110d) and PIK3R1 (encoding
p85a) were described in individuals diagnosed with pri-
mary immune deficiencies [62,63,64–67]. These
patients suffer from severe recurrent respiratory infec-
tions and have increased susceptibility to lymphoma. B
cells from the patients were defective in immunoglobulin
class switching. Many patients also presented with T cell
lymphopenia associated with increased numbers of
senescent T cells. Stimulation of patient T cells resulted
in low cytokine production and increased activation-
induced cell death, which could be partially rescued by
the addition of IC87114 which also reduced PIP3 levels
[62,66]. These results indicate that idelalisib, or other
PI3Kd inhibitors under development, could significantly
improve the outcome of immune-deficient patients with
activating p110d or p85a mutations. Also, in one patient,
rapamycin treatment restored normal T cell populations
[63]. It remains to be determined whether an oral or
inhaled route of administration would be preferable in
these severely affected patients, and this is likely to
depend on the disease profile of the individual patient
and the specific side effects associated with each route.
Class I PI3K and cancer
The PI3K/AKT/mTOR pathway is of critical importance
in tumour development and PIK3A (encoding p110a) as
well as PTEN are among the most frequently mutated in
human cancers. This provides a strong rationale for pan-
class I as well as PI3Ka and PI3Kb selective inhibition in
treating solid cancers expressing these isoforms. Initially
this strategy was met with limited success, mainly due to
dose-limiting side effects and development of resistance
due to negative feedback mechanisms activating alterna-
tive survival pathways. These issues can be addressed by
combination-therapies inhibiting several signalling nodes
at once, and current strategies for targeted inhibition of
PI3Ka and PI3Kb were recently reviewed [5,56,68].
PI3Kd and PI3Kg are potential targets in haematological
cancers, and a notable success is the development of
idelalisib which has shown remarkable efficacy in treating
Chronic Lymphocytic Leukaemia (CLL) and non-Hodg-
kin’s lymphoma, and is now approved for clinical use
[59,60,69].
In addition to targeting the PI3K pathway to inhibit
tumour cell growth directly, PI3K inhibitors may also
be used to improve anti-tumour immune responses. Ge-
netic or pharmacological inhibition of PI3Kd (PI-3065)
reduced tumour burden and metastasis in a range of
mouse cancer models including melanoma, thymoma,
lung, breast and pancreatic cancer [41]. In these models,
PI3Kd inhibition attenuated Treg function and tumour
infiltration while leaving the cytotoxic T cell response
relatively unscathed, resulting in enhanced anti-tumourCurrent Opinion in Pharmacology 2015, 23:82–91
88 Immunomodulationimmunity. PI3Kd inhibition can also alleviate graft versus
host disease while maintaining strong graft versus leu-
kaemia effect [70].
Genetic or pharmacological inactivation of p110g using
TG100-115 and AS605240 was also found to reduce
tumour growth and metastasis in melanoma, lung, pan-
creatic and breast cancer models. PI3Kg signalling was
required for myeloid cell recruitment to the tumour
microenvironment through integrin a4b1 mediated ad-
hesion, in response to growth factors and chemokines.
Therefore, inhibition of p110g signalling was effective in
reducing general tumour associated inflammation and
angiogenesis without affecting systemic numbers of my-
eloid cells [4].
Dual p110d/p110g inhibitors are already in clinical trials
for haematological cancers, and are effective in control-
ling inflammation [30]. It would therefore be interesting
to evaluate the effect of these compounds on anti-tumour
immune responses in solid cancer models.
Class II PI3K
Class II PI3K phosphorylate PIP and PI4P to form PI3P
and PI(3,4)P2 respectively. Although the biology of class
II PI3K signalling is still incompletely understood recent
progress have indicated a role for PI3KC2 isoforms in
immune cell signalling and tumour development [71].
However, because selective inhibitors against the class II
PI3Ks have yet to be described, we do not consider this
class further in this review.
Class III PI3K
Vps34 phosphorylate PIP to form PI3P at the pre-autop-
hagosome or endosome leading to the recruitment of
FYVE and PX domain containing proteins [1,2,72].
Vps34 associates with the protein kinase Vps15 in different
protein complexes, and play an important role in mem-
brane trafficking and protein sorting pathways. PI3P pro-
duced by Vps34 is critical for autophagosome and
phagosome maturation as well as NOX2 mediated ROS
production, thereby playing a key role in autophagy, as well
as pathogen uptake and killing by innate immune cells.
Autophagy maintains normal cell function by removing
misfolded proteins and damaged organelles, but also has
specialised functions in the immune system. Autophagy
mediates intracellular TLR activation by bringing cyto-
plasmic antigens in contact with TLR in the lysosome, and
promotes cross-presentation of intracellular antigens on
MHCII [2]. T cell-specific loss of Vps34 impairs invariant
NKT cell development and peripheral T cell homeostasis,
which ultimately lead to intestinal inflammation and wast-
ing syndrome as a result of Treg dysfunction [73].
Recently three independent groups published selective
Vps34 inhibitors: SAR405, PIK-III and Vps34-IN1Current Opinion in Pharmacology 2015, 23:82–91 [74,75,76,77]. These compounds will increase our un-
derstanding of the functions performed by Vps34 and
opens up the possibility to target this kinase for thera-
peutic benefit. Already, SAR405 was found to act syner-
gistically with the mTOR inhibitor everolimus to reduce
proliferation in a renal tumour cell line [74], while PIK-
III was used to identify a novel autophagy substrate:
NCOA4 binds ferritin and plays a role in recycling iron
from red blood cells in the spleen [75]. VPS34-IN1
revealed that class I and class II PI3K activity contribute
to PIP3 mediated activation of SGK3 [76
]. This opens up
the possibility that synergistic class I PI3K and Vps34
inhibitors could be used in the treatment of tumours with
elevated SGK3 activity. Whether Vps34 inhibitors have
potential for use in immune-mediated diseases remains to
be explored: germ-line loss of Vps34 is embryonically
lethal, and tissue specific deletion found a critical role for
Vps34 in normal neuron, heart and liver function [78].
However, further study is required to establish if systemic
Vps34 inhibition will be tolerated.
Conclusion
Although much progress has been made in understanding
the role of PI3K signalling in inflammation and cancer,
many questions still remain. PI3K signalling plays a
complex and often opposing role in the regulation of
immune responses and the effect of inhibiting PI3K is
dependent on the context of activation. The factors
modulating opposing functions of PI3K signalling are
not yet clearly understood and warrant further investiga-
tion. This complexity of PI3K pathway regulation poses
an interesting challenge for the therapeutic application of
PI3K inhibitors: a better understanding of which isoforms
are critical in different disease mechanisms and to what
extent inhibition is favourable or not is essential. Animal
models and early clinical trials show great potential in
therapeutic targeting of this pathway in immune-related
disorders and cancer, but do not always predict clinical
efficacy.
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